ArticlePhysics and imaging in radiation oncology2026
3D analysis and evolution of prostate and tumor oxygenation using MRI-derived relative oxygen extraction fraction during MR-guided stereotactic body radiotherapy.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Purpose: Tumor hypoxia is a major cause of radioresistance, motivating the development of biomarkers related to tissue oxygen physiology that can be monitored throughout treatment. MRI-derived relative Oxygen Extraction Fraction (rOEF) is a non-invasive imaging biomarker related to tissue oxygen extraction. This study characterized the temporal evolution of rOEF during MR-guided stereotactic body radiotherapy (MRgSBRT) for prostate cancer. Materials/Methods: Twenty-three prostate cancer patients treated with five-fraction MRgSBRT were analyzed. rOEF maps were acquired at treatment planning and at each treatment fraction. Average rOEF was extracted from the healthy prostate, gross tumor volume (GTV), and two gluteal muscle regions receiving either residual (in-field) or negligible (out-of-field) irradiation. Longitudinal changes in average rOEF and in the fraction of GTV voxels with rOEF >70% were quantified using patient-specific linear fits. Slopes of average rOEF in the healthy prostate were also calculated between successive imaging sessions. Results: Average rOEF decreased significantly in all irradiated regions (healthy prostate, GTV and in-field gluteal muscle), with no significant change in the out-of-field gluteal muscle. The fraction of GTV voxels with rOEF >70% also declined significantly. In the healthy prostate, rOEF decreased predominantly during the first four fractions, with the steepest median slope observed between planning and the first treatment fraction (-3.2). Conclusions: MRgSBRT was associated with a progressive reduction in rOEF confined to irradiated tissues, with the largest decrease in healthy prostate rOEF occurring after the first irradiation. These findings suggest rOEF could be a potential imaging biomarker of physiological changes associated with radiation exposure and warrant further investigation of its relationship with physiological processes and tissue hypoxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.